Tarlatamab and temozolomide for brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older.
- You must have a brain tumor (such as a high-grade glioma) that is getting worse despite standard treatment, and your tumor cells must have a protein called DLL3.
- You must have completed chemotherapy or radiation at least 3 weeks (and sometimes longer) before starting this trial.
- You must be in fairly good health, able to care for yourself, with adequate blood counts, kidney and liver function.
- You cannot have certain other medical conditions, like active infections, autoimmune diseases, or past severe reactions to similar drugs.
- Women who could become pregnant and men must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug called tarlatamab is safe and effective for people with certain types of brain tumors that have an IDH mutation. You may be eligible if you have had up to 2 prior treatments after the tumor returned, and you are either having surgery to remove the tumor or the tumor cannot be removed.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial tests a daily chemo drug (temozolomide) in patients aged 65 or older with a specific type of aggressive brain cancer that has a certain genetic marker. It aims to see if this daily schedule works well after initial radiation and chemo.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial studies whether giving the drug tarlatamab before and after surgery can help treat recurrent high-grade glioma (a type of brain cancer). It aims to see if this approach is safe and effective for patients who are eligible for surgery.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.